LAK细胞对眼部恶性肿瘤的免疫治疗临床观察  

CLINICAL OBSERVATION OF IMMUNOTHERAPY IN OCULAR MALIGNANT TUMORS WITH LYMPHOKINE-ACTIVATED KILLING (LAK) CELL

作　　者：杨良户[1] 王虹[1] 张先南[1] 张菊[2] 梁国栋[2] 

机构地区：[1]第四军医大学西京医院眼科 [2]唐都医院中心实验室

出　　处：《眼科学报》1993年第2期51-54,共4页Eye Science

摘　　要：本文应用 rIL-2体外诱导自身 LAK(Lynphokine-Activated Killing)细胞,对眼部恶性肿瘤病人进行瘤区局部治疗,取得较好的疗效,16例恶性肿瘤中,基底细胞癌5例;完全消退4例,部分消退1例,睑板腺癌4例,鳞状细胞癌2例,视网膜母细胞瘤,眶内非何杰金氏淋巴瘤,眶内血管外皮瘤,眶内纤维组织细胞瘤(生长活跃),汗腺癌各1例,都获完全消退.以上结果表明,病人自身 LAK 细胞局部治疗是一种有效的免疫方法.眼科学报 1993;9:51-54。In this paper,the authors reported the method of treating ocular malignant tumors with lymphokine-activated killing cells which were induced by rIL-2 in vitro.Among the sixteen cases of ocu- lar tumors,4 cases of 5 base cell carcinoma(1 case of which was partially extinctive),4 cases of tarsal gland carcinoma,2 cases of squamous cell carcinoma and respectively 1 case of retinoblastoma,non- Hodykin's lymphoma,intraobital hemangiopericytoma,intraobital fibrous histiocytomas and hidradeno- carcinoma were completely extinctive.The result shows that the immunotherapy method is effective.Eye Science 1993;9:51-54.

关 键 词：眼肿瘤 杀伤细胞 免疫疗法 

分 类 号：R739.705[医药卫生—肿瘤]